Navigation Links
Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
Date:4/27/2009

of testosterone.(1)(2) Suppression of testosterone to castrate levels occurred significantly faster in patients receiving degarelix than in those receiving leuprolide.(1)(2) At Day 3 of treatment, the degarelix group achieved a 90 percent decrease in median testosterone levels compared with the leuprolide group, which experienced a 65 percent increase in median testosterone levels, a statistically significant result. Degarelix was as effective as leuprolide in suppressing testosterone levels from Day 28 to the end of the study (Day 364), with 97.2 percent of the degarelix patients maintaining medical castrate levels compared with 96.4 percent for leuprolide.

In addition, prostate-specific antigen (PSA) levels were lowered by 64 percent two weeks after administration of degarelix, 85 percent after one month, 95 percent after three months, and remained suppressed throughout the one year of treatment.(1)(2) These PSA results should be interpreted with caution because of the heterogeneity of the patient population studied. No evidence has shown that the rapidity of PSA decline is related to a clinical benefit.

About Degarelix

Degarelix is an injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer. As a receptor antagonist, degarelix reversibly binds to the GnRH receptors in the pituitary gland, immediately suppressing the secretion of the luteinizing hormone (LH), follicle-stimulating hormone (FSH), and subsequently, testosterone levels.(3) Degarelix also reduces levels of prostate-specific antigen (PSA). Unlike luteinizing hormone-releasing hormone (LHRH) agonists, such as leuprolide, an established treatment for prostate cancer, degarelix does not induce an initial testosterone surge. Degarelix is administered monthly by subcutaneous injection. The starting dose is 240 mg, fol
'/>"/>

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Research and Markets has announced the addition of the ... Disorder) Market - Forecast to 2023" report to their ... human microbiome market is segmented by application, disease, product, and ... be valued as $294 million in 2019 and is poised ... period of 2019-2023. The market is driven by growing incidences ...
(Date:9/19/2014)... UBM Medica US announces that  ... help oncologists and other clinicians gain a better understanding ... targeted therapies and immunotherapies, discusses some of the latest ... Every September, Blood Cancer Awareness Month ... blood cancers—helping to increase survival rates and improve the ...
(Date:9/19/2014)... WALTHAM, Mass. , Sept. 19, 2014  Alere ... in rapid diagnostics, issued the following statement today in ... Combating Antibiotic-Resistant Bacteria. "As the global leader ... President for establishing a national strategy to address the ... continuing to work with the Administration on initiatives to ...
Breaking Medicine Technology:Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
(Date:9/19/2014)... kids transition from elementary to middle school, they are ... study. But the researchers studying U.S schoolkids ... physical bullying declines as students get older. Because ... address all types of bullying as well as differences ... The study was published recently in School Psychology ...
(Date:9/19/2014)... 19, 2014 Hastings and Hastings, a discount ... the industry, announces a record number of visitors to its ... variety of serious injury cases as well as auto accident ... bite related accident cases and others. Having served the state ... stood the test of time when it comes to dedicated ...
(Date:9/19/2014)... Rockville Centre, NY (PRWEB) September 19, 2014 ... 17, the manufacturers of the embattled blood-thinner Xarelto, named ... County Court of Common Pleas, have moved the court ... the cases do not have sufficient connection with Philadelphia.* ... & Development, et al. (No. 140304328; Pa. Comm. Pls., ...
(Date:9/19/2014)... -- Your brain structure could help predict how willing you ... Researchers at Yale University found those with greater volume in ... may be more likely to engage in risky behavior than ... study, funded by the U.S. National Institute on Aging, involved ... the Northeast. The researchers sought to determine how brain structure ...
(Date:9/19/2014)... 2014 (HealthDay News) -- The U.S. Food and Drug Administration ... Trulicity is part of a class of once-a-week injectable drugs ... 2 diabetes. "Trulicity is a new treatment option, ... regimens to control blood sugar levels in the overall management ... the FDA,s Office of Drug Evaluation II, said in an ...
Breaking Medicine News(10 mins):Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Brain Structure Might Help Predict Risky Behavior 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2
... child filed a motion in federal court today to confirm settlement ... The family alleged in the suit that the insurer wrongfully ... (ASD), on the baseless ground that the care was "experimental." ... at a court-ordered conference on Wednesday, June 17, 2009, Blue Cross ...
... between gray matter and dopamine levels in patients , ... levels of the neurotransmitter dopamine may explain brain gray ... study suggests. , Previous research found an association between ... wasn,t known, the researchers wrote. , In this new ...
... treatment delays and jeopardize care, review suggests, , FRIDAY, June ... lecturer at the University of Toronto, was enjoying a rare ... beeped. , "I answered the page, and there was the ... been calling repeatedly to try to get in touch with ...
... , Brio Active opens its doors this month, offering a ... its core. , , DENVER, June 19 Brio ... vibration, a relatively new fitness concept in the U.S., with ... strength, flexibility, balance, energy, bone density, and neuromuscular coordination. ...
... 19 Bertalan Mesko, medical blogger and health 2.0 consultant, ... by Federico Semeraro, MD and the D-Sign Team, that provides ... but not everyone is trained to be able to perform ... to do it through clear instructions and images. , ...
... WHITE PLAINS, N.Y., June 19 Kenneth A. May, former CEO ... Trustees of the March of Dimes, it was announced today. , ... for our mission, especially our Prematurity Campaign," said Dr. Jennifer L. ... Ken,s continued leadership as we work towards our goal of giving ...
Cached Medicine News:Health News:Blue Cross Blue Shield of Michigan Forced to Pay for Autism Care In Landmark Case 2Health News:Blue Cross Blue Shield of Michigan Forced to Pay for Autism Care In Landmark Case 3Health News:Pages to Doctors Don't Always Hit the Mark 2Health News:Pages to Doctors Don't Always Hit the Mark 3Health News:Brio Active Brings Whole Body Vibration Fitness to Cherry Hills Village 2
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Medicine Products: